Nsv Partners Iii Lp, a major shareholder, sold 90,565 of the company's shares in a deal that took place on Monday, 24th April. The shares were purchased at an average of $38.64 for a value of $3 499 431.60. After the sale was completed, the insider owns directly 9,877,838 of the company's shares, valued at about $381,679 660.32. The SEC requires large shareholders who own at least 10% in a company to report their sales and purchases.
Nsv Partners Iii Lp has also made recent trades in the following areas:
Nsv Partners Iii Lp has sold 8,642 Ventyx Biosciences shares on Friday, April 21, 2019. The stock was bought at an average of $37.51, resulting in a transaction totaling $324,161.42.
Nsv Partners Iii Lp has sold 71 446 Ventyx Biosciences shares on Thursday, the 13th of April. The shares were purchased at a price of $30.31 on average, totaling $2,165.528,26.
On Tuesday, the stock fell $1.49 to $37.66. The average trading volume for the stock is 835,960 shares. The stock's market cap is $2.19 billion. It has a P/E ratio of -18.37, and a beta value of -0.36. The 50-day moving average of the business is $37.67, and its 200-day moving average is 33.99. Ventyx Biosciences, Inc.'s twelve-month low is $11.07, and its twelve-month high is $47.25.
Analyst Ratings Changes
VTYX was the subject of several research analyst reports. Wells Fargo & Company began covering Ventyx Biosciences shares in a report published on Monday, 20th March. The stock was given an 'overweight rating' and a target price of $77.00. Canaccord Genuity Group raised their price target on Ventyx Biosciences to $54.00 in a research report on Tuesday, 31st January. The company was also given a "buy" rating. Evercore ISI increased their price target on Ventyx Biosciences in a report published on Thursday, January 26, from $50.00 up to $65.00. Oppenheimer reduced their Ventyx Biosciences target price from $65.00 down to $62.00 in a Friday, March 24, report. They also set an "outperform" rating for the stock. According to MarketBeat data, eight research analysts rated the stock as a buy.
Inflows of Institutional Capital and Outflows
VTYX has recently seen a number of institutional and hedge fund investors increase or decrease their stakes. Bank of New York Mellon Corp increased its holdings of Ventyx Biosciences from 38.1% to $1.25 million in the first quarter. Bank of New York Mellon Corp owns 24,242 of the company’s stock worth $329,000, after buying 6,688 additional shares. Charles Schwab Investment Management Inc. increased its stake in Ventyx Biosciences shares by 3.5% during the first quarter. Charles Schwab Investment Management Inc. owns now 73,803 of the company’s stock worth $1,002,000, after purchasing an additional 2,482 during the period. State Street Corp increased its stake in Ventyx Biosciences during the first quarter by 65.2%. State Street Corp owns 171,195 of the company’s shares worth $2,323,000, after purchasing an additional 67 590 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Ventyx Biosciences from 57.8% to $2,323,000 during the second quarter. JPMorgan Chase & Co. owns 11,984 of the company’s shares worth $147,000, after acquiring 4,391 additional shares during the period. Rhumbline Advisers purchased a new position of $311,000 in Ventyx Biosciences during the second quarter. Institutional investors and hedge fund own 95,57% of the company's stock.
Ventyx Biosciences, Inc., a biopharmaceutical clinical-stage company, develops product candidates based on small molecules to treat a variety of inflammatory disorders. The company's leading clinical product candidate, VTX958, is a selective allosteric tyrosine kinase 2 inhibitor that targets psoriasis and psoriatic joint disease.
MarketBeat.com offers a FREE daily email newsletter